Naslov
Pharmacoeconomic modelling of Alzheimer's disease - assessment of mementine in treating moderate to severe Alzheimer patients

Autori
Benković, Vanesa ; Mimica, Ninoslav ; Stevanović, Ranko

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, stručni

Izvornik
Abstracts of the 51st International Neuropsychiatric Pula Congress (INPC). U: Acta clinica Croatica 50 (2011)(S2) Posters Neurology / Rotim, Krešimir - Zagreb, 2011, 104-104

Skup
51st International Neuropsychiatric Pula Congress

Mjesto i datum
Pula, Hrvatska, 15.06.2011. - 18.06.2011

Vrsta sudjelovanja
Poster

Vrsta recenzije
Međunarodna recenzija

Ključne riječi
pharmacoeconomic ; modelling ; Alzheimer's disease ; memantine ; moderate ; severe

Sažetak
Introduction/Objectives: In treating of moderate to severe Alzheimer patients, N-methyl D-aspartat antagonist memantine has demonstarated better results and correlations with decreased hospitalization rate, thus decreasing total health costs. Most of pharmacoeconomic studies for this disease consider societal perspective using cost effectiveness principle and QUALY parameters. This paper considers payer perspective (Croatian Department for Health Insurance) and takes into account direct cost of the disease as requested in Croatian guidelines for drugs reimbursement. Recent NICE (National Institute for Clinical Excellence) memantine coverage enabled more space for this drug's reimbursement in other countries. The aim of the paper was to assess direct cost of illness with and without treatment with memantine, through a three year perspective. Participants, Materials/Methods: Due to lack of (inaccurate) epidemiological data, authors have undertaken further data search : the paper demonstrates cost variables taken from Croatian real life environment of treating Alzheimer patients acquired by delphi consensus method. Markov model was created for Croatian case to assess effect of the drug on hospitalization frequency and other direct treatment costs. Model stability was tested with Monte Carlo simulations. Results: Results demonstrate memantine domination in terms of efficiency and cost reduction. Reduced and delayed hospitalization relate to direct costs, while less antipsychotic use, commorbidities and caregiver effort evidenced lower other costs. Conclusions: Memantine brings substantial cost savings on annual as well as three annual time horizon. It may be concluded that memantine reimbursement may bring cost savings not only to health budget of the payer, but also to other hospital related costs.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti

POVEZANOST RADA